vaccine construction and its uses against staphylococcus infections. A fusion construct of the formula (i) is provided: xa-binder-bz (i) wherein: (1) a and b are identical or different and are independently: (a) a polypeptide comprising a sacol0029 polypeptide as shown in any one of the following: sequences shown in fig. 24 (id seq. No .: 5 and 121 to 131), a sacol0264 polypeptide (id seq: 185), a sacol0442 polypeptide as shown in any of the sequences shown in fig. 22d (id seq. No .: 29 and 82 to 92), a sacol0718 polypeptide (id seq. No. 186), a sacol0720 polypeptide as shown in any of the sequences depicted in figs. 23i-j (id seq. No. 11 and 109 to 120), a sacol1353 polypeptide (id seq. No. 187), a sacol1416 polypeptide (id. Seq. No .: 188), a sacol1611 polypeptide (seq. Id .: 189) a sacol1867 polypeptide as shown in any of the sequences shown in fig. 25d (id seq: 152 to 164), a sacol1912 polypeptide (id seq: 43), a sacol1944 polypeptide (id seq: 190), a sacol2144 polypeptide (seq id: 191), a sacol2365 polypeptide (id seq no .: 192), a sacol2385 polypeptide (id seq no .: 50) or a sacol2599 polypeptide (id seq no .: 193) based on the genetic nomenclature of the staphylococcus aureus col (sacol) genome established in ncbi reference sequence nc_002951.2； (b) a polypeptide encoded by a gene of the same operon as a gene encoding the polypeptide of (a)； (c) a polypeptide comprising an immunogenic fragment of at least 13 consecutive amino acids from (a) or (b)； (d) a polypeptide comprising an amino acid sequence at least 60% overall identical to the polypeptide sequence of any one of (a) to (c)； or (e) a polypeptide comprising an immunogenic variant comprising at least 13 consecutive amino acids from any of (a) to (c)； (2) the binder is an amino acid sequence of at least one amino acid or is absent； (3) x is absent or is an amino acid sequence of at least one amino acid； and (4) z is absent or is an amino acid sequence of at least one amino acid. Also provided are composi
